Parkman Healthcare Partners’s Alnylam Pharmaceuticals ALNY Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $30.1M | Buy |
92,338
+23,400
| +34% | +$7.63M | 3.46% | 4 |
|
|
2025
Q1 | $18.6M | Buy |
68,938
+30,266
| +78% | +$8.17M | 2.21% | 14 |
|
|
2024
Q4 | $9.1M | Buy |
38,672
+13,187
| +52% | +$3.1M | 1.21% | 32 |
|
|
2024
Q3 | $7.01M | Buy |
+25,485
| New | +$7.01M | 0.89% | 42 |
|
|
2022
Q4 | – | Sell |
-10,873
| Closed | -$2.18M | – | 82 |
|
|
2022
Q3 | $2.18M | Sell |
10,873
-9,861
| -48% | -$1.97M | 0.62% | 53 |
|
|
2022
Q2 | $3.02M | Sell |
20,734
-33,274
| -62% | -$4.85M | 1.11% | 32 |
|
|
2022
Q1 | $8.82M | Sell |
54,008
-3,674
| -6% | -$600K | 2.58% | 12 |
|
|
2021
Q4 | $9.78M | Sell |
57,682
-17,285
| -23% | -$2.93M | 2.16% | 16 |
|
|
2021
Q3 | $14.2M | Hold |
74,967
| – | – | 3.58% | 6 |
|
|
2021
Q2 | $12.7M | Buy |
74,967
+9,924
| +15% | +$1.68M | 2.78% | 10 |
|
|
2021
Q1 | $9.18M | Buy |
65,043
+28,882
| +80% | +$4.08M | 2.13% | 12 |
|
|
2020
Q4 | $4.7M | Buy |
36,161
+5,298
| +17% | +$689K | 1.2% | 32 |
|
|
2020
Q3 | $4.49M | Sell |
30,863
-5,000
| -14% | -$728K | 1.19% | 37 |
|
|
2020
Q2 | $5.31M | Sell |
35,863
-500
| -1% | -$74.1K | 1.5% | 28 |
|
|
2020
Q1 | $3.96M | Buy |
36,363
+1,363
| +4% | +$148K | 1.83% | 21 |
|
|
2019
Q4 | $4.03M | Buy |
+35,000
| New | +$4.03M | 1.16% | 29 |
|